164 related articles for article (PubMed ID: 28760447)
21. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
[TBL] [Abstract][Full Text] [Related]
22. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
Pitarokoili K; Gold R
Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
[No Abstract] [Full Text] [Related]
23. Natalizumab therapy is associated with changes in serum JC virus antibody indices over time.
Peters J; Williamson E
J Neurol; 2017 Dec; 264(12):2409-2412. PubMed ID: 29034436
[TBL] [Abstract][Full Text] [Related]
24. JC viremia in natalizumab-treated patients with multiple sclerosis.
Major EO; Frohman E; Douek D
N Engl J Med; 2013 Jun; 368(23):2240-1. PubMed ID: 23738566
[No Abstract] [Full Text] [Related]
25. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Carruthers RL; Chitnis T; Healy BC
Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
[TBL] [Abstract][Full Text] [Related]
26. Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
Rossi F; Prosperini L; De Rossi N; Capra R; Rivanera D; Li X; Cinque P; Passeri L; Pozzilli C; Viscidi R
Viral Immunol; 2017 Oct; 30(8):622-626. PubMed ID: 28836899
[TBL] [Abstract][Full Text] [Related]
27. Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
Baber U; Bouley A; Egnor E; Sloane JA
J Neurol; 2018 Oct; 265(10):2342-2345. PubMed ID: 30109480
[TBL] [Abstract][Full Text] [Related]
28. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
Schweitzer F; Ladwig A; Opala S; Laurent S; Schroeter M; Goelz S; Fink GR; Wieland U; Silling S; Warnke C
Mult Scler Relat Disord; 2024 Jul; 87():105664. PubMed ID: 38735204
[TBL] [Abstract][Full Text] [Related]
29. Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.
Hegen H; Auer M; Bsteh G; Di Pauli F; Plavina T; Walde J; Deisenhammer F; Berger T
PLoS One; 2017; 12(3):e0174005. PubMed ID: 28319193
[TBL] [Abstract][Full Text] [Related]
30. John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.
van Kempen ZLE; Leurs CE; de Vries A; Vennegoor A; Rispens T; Wattjes MP; Killestein J
Eur J Neurol; 2017 Sep; 24(9):1196-1199. PubMed ID: 28707781
[TBL] [Abstract][Full Text] [Related]
31. Improving risk-stratification of natalizumab-associated PML.
Tugemann B; Berger JR
Ann Clin Transl Neurol; 2021 Mar; 8(3):696-703. PubMed ID: 33539683
[TBL] [Abstract][Full Text] [Related]
32. Considerations for characterizing the risk of PML in natalizumab-treated patients.
Koendgen H; Ho PR; Chang I
Mult Scler Relat Disord; 2016 Sep; 9():121. PubMed ID: 27645357
[No Abstract] [Full Text] [Related]
33. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
Miranda Acuña JA; Weinstock-Guttman B
Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
[TBL] [Abstract][Full Text] [Related]
34. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
35. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Warnke C; Ramanujam R; Plavina T; Bergström T; Goelz S; Subramanyam M; Kockum I; Rahbar A; Kieseier BC; Holmén C; Olsson T; Hillert J; Fogdell-Hahn A
J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1199-205. PubMed ID: 23463870
[TBL] [Abstract][Full Text] [Related]
36. Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr virus and -measles/-rubella/-varicella-zoster-virus antibodies.
Auer M; Borena W; Holm-von Laer D; Deisenhammer F
J Med Virol; 2017 Jan; 89(1):3-9. PubMed ID: 27253624
[TBL] [Abstract][Full Text] [Related]
37. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
[TBL] [Abstract][Full Text] [Related]
38. Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.
Auer M; Hegen H; Sellner J; Oppermann K; Bsteh G; Di Pauli F; Berger T; Deisenhammer F
Brain Behav; 2019 Jul; 9(7):e01332. PubMed ID: 31168964
[TBL] [Abstract][Full Text] [Related]
39. Anti-JC Virus Antibodies in a Large German Natalizumab-Treated MS Cohort.
Zahednasab H
Neurology; 2012 Nov; 79(19):2010; author reply 2010-1. PubMed ID: 23128444
[No Abstract] [Full Text] [Related]
40. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
